FIRST QUARTER 2017 AND RECENT KEY ACHIEVEMENTS

- Initiated pre-clinical safety and efficacy studies at two leading US institutions to evaluate the Company’s revolutionary self-cleaning shunt (SCS), which is designed to prevent obstruction in Cerebrospinal Fluid Catheters.

- Received an issuance of allowance for a patent covering a device for the prevention of shunt stenosis, specifically in the hemodialysis space. The Company believes this provides another area of future growth as well as an additional layer of protection to its innovative technology platforms, extending beyond its current IP protected applications.

- Enhanced its Board of Directors with the addition of Martin Madden, a seasoned healthcare executive who had spent his entire career in the medical device market, primarily at Johnson & Johnson.

- Expanded the management team with the addition of Eran Cohen, Director of Business Development. Mr. Cohen is a proven leader in the medical device space and his primary focus will be on continuing the Company’s partnerships and collaborative activities as well as continue exploring areas of growth opportunities leveraging the Company’s two technology platforms, TipCAT and ViRob.

- Strengthened balance sheet with proceeds of $3.5 million from the sale of the Company’s common stock.
Addressing multi-billion, high growth, underserved markets

Initial neuro and GI products with comprehensive value propositions poised to be submitted for FDA approval within 24 months

Developing two micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs

Significant IP creates barrier to entry

Potential pipeline designed to deliver additional solutions to other medical conditions every 12–24 months

Proven leadership team, includes Prof. Moshe Shoham, founder of Mazor Robotics (NASDAQ: MZOR)

The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body [https://www.youtube.com/watch?v=_cs2cRl3Ile]. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time.

To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/

TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body.

To learn more about TipCAT visit http://www.microbotmedical.com/technology/tipcat/

The statements in this document that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Microbot’s products, as well as its proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Microbot’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Microbot’s products, proprietary technologies and their uses, and competition from other biopharmaceutical companies. Certain of these factors and others are more fully described in Microbot’s filings with the Securities and Exchange Commission.